ReviewAdvanced healthcare materials2025
Microphysiological Systems for Comorbidity Studies: Chronic Kidney Disease and Osteoarthritis.
Review in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Multi‑omics integration in osteoarthritis: Unraveling cell‑type‑specific gene‑metabolite networks for precision medicine (Review).International journal of molecular medicine · 2026Review
- Regenerative and Stem Cell-Based Therapies for Arthritis: Harnessing Mesenchymal Stem Cells, Exosomes, and Bioengineered Scaffolds for Functional Joint Repair.Stem cell reviews and reports · 2026Review
- Article
- Microphysiological Systems for Comorbidity Studies: Chronic Kidney Disease and Osteoarthritis.Advanced healthcare materials · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The global increase in chronic diseases and comorbidities due to aging populations is placing significant strain on healthcare systems. Chronic kidney disease (CKD) and osteoarthritis (OA) are among the most prevalent conditions in the elderly, with complex interconnections driven by shared risk factors such as systemic inflammation and metabolic dysregulation. Despite the critical need to understand these interactions, traditional animal models often fail to adequately capture the multidirectional crosstalk between human comorbid conditions, limiting insights into their mechanisms and complicating translational research. Advancements in microphysiological systems (MPS), which also known as organ-on-a-chip (OoC) technologies, offer a promising alternative for studying comorbidities, such as CKD-OA. MPS, which integrate human cells within biomimetic, bioengineered platforms, replicate the structural and functional properties of human tissues with unparalleled physiological relevance. This review explores the transformative potential of MPS technology in comorbidity research, focusing on CKD-OA as a case study. Kidney-on-a-chip and joint-on-a-chip models and their applications in CKD and OA modeling are summarized and discussed. Furthermore, multi-organ-on-a-chip systems are = discussed for their potential to model comorbidities = and support the development of safer and more effective disease treatment strategies. This review underscores the potential of MPS to revolutionize comorbidity research and pave the way for personalized therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.